Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBT (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EBT for 16 consecutive years, with $71.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 3.07% year-over-year to $71.9 million, compared with a TTM value of $283.5 million through Dec 2025, up 31.1%, and an annual FY2025 reading of $283.5 million, up 31.1% over the prior year.
  • EBT was $71.9 million for Q4 2025 at Catalyst Pharmaceuticals, up from $71.0 million in the prior quarter.
  • Across five years, EBT topped out at $74.2 million in Q4 2024 and bottomed at -$38.0 million in Q3 2023.
  • Average EBT over 5 years is $37.6 million, with a median of $35.2 million recorded in 2022.
  • The sharpest move saw EBT tumbled 246.2% in 2023, then surged 250.46% in 2024.
  • Year by year, EBT stood at $12.8 million in 2021, then surged by 157.61% to $33.0 million in 2022, then soared by 41.5% to $46.7 million in 2023, then skyrocketed by 58.82% to $74.2 million in 2024, then dropped by 3.07% to $71.9 million in 2025.
  • Business Quant data shows EBT for CPRX at $71.9 million in Q4 2025, $71.0 million in Q3 2025, and $69.3 million in Q2 2025.